The Structure of Streptomyces wadayamensis MppR

Mentor 1

Nicholas R. Silvaggi

Location

Union Wisconsin Room

Start Date

24-4-2015 2:30 PM

End Date

24-4-2015 3:45 PM

Description

Antibiotic discovery has slowed dramatically, while the occurrence of antibiotic-resistant infections is increasing. The microbial world has furnished modern medicine with a remarkable array of antibiotic compounds. Many of the most important drugs in the clinic are themselves, or are derived from, chemicals naturally produced by bacteria and fungi. For every viable antibiotic, however, there are many promising compounds that ultimately fail to become drugs. One such compound is mannopeptimycin (MPP), a cyclic glycopeptide antibiotic produced by Streptomyces wadayamensis that has potent activity against problematic pathogens like methicillin-resistant Staphylococcus aureus (MRSA). Mannopeptimycin has not become a clinically-viable antibiotic because it is too toxic to mammalian cells. In theory, it might be possible to develop analogs of mannopeptimycin, but these efforts are hampered by the fact that a key part of the pharmacophore of MPP, the non-proteinogenic amino acid L-enduracididine (L-End) is not commercially available and is very difficult to produce synthetically. Without this key building block, it is difficult to make MPP analogs. To address this problem, our lab is studying how S. wadayamensis produces L-End. The biosynthetic pathway is thought to originate from arginine and involves the action of three enzymes: MppP, MppQ, and MppR. None of these enzymes have a known biochemical function. We have determined the structure of MppR, which shows that its overall structure is very similar to that of acetoacetate decarboxylase. However, MppR does not display decarboxylase activity with acetoacetate or any alpha- or beta-keto acid we tested. Thus, more work is needed to identify the role of MppR in the production of L-End. /

This document is currently not available here.

Share

COinS
 
Apr 24th, 2:30 PM Apr 24th, 3:45 PM

The Structure of Streptomyces wadayamensis MppR

Union Wisconsin Room

Antibiotic discovery has slowed dramatically, while the occurrence of antibiotic-resistant infections is increasing. The microbial world has furnished modern medicine with a remarkable array of antibiotic compounds. Many of the most important drugs in the clinic are themselves, or are derived from, chemicals naturally produced by bacteria and fungi. For every viable antibiotic, however, there are many promising compounds that ultimately fail to become drugs. One such compound is mannopeptimycin (MPP), a cyclic glycopeptide antibiotic produced by Streptomyces wadayamensis that has potent activity against problematic pathogens like methicillin-resistant Staphylococcus aureus (MRSA). Mannopeptimycin has not become a clinically-viable antibiotic because it is too toxic to mammalian cells. In theory, it might be possible to develop analogs of mannopeptimycin, but these efforts are hampered by the fact that a key part of the pharmacophore of MPP, the non-proteinogenic amino acid L-enduracididine (L-End) is not commercially available and is very difficult to produce synthetically. Without this key building block, it is difficult to make MPP analogs. To address this problem, our lab is studying how S. wadayamensis produces L-End. The biosynthetic pathway is thought to originate from arginine and involves the action of three enzymes: MppP, MppQ, and MppR. None of these enzymes have a known biochemical function. We have determined the structure of MppR, which shows that its overall structure is very similar to that of acetoacetate decarboxylase. However, MppR does not display decarboxylase activity with acetoacetate or any alpha- or beta-keto acid we tested. Thus, more work is needed to identify the role of MppR in the production of L-End. /